Press Releases

18.11.2015

The biotechnology company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present two posters on the immunotherapy MGN1703 at the ESMO Symposium on Immuno-Oncology 2015 (ESMO IO) in Lausanne (20 – 21 November 2015).

12.11.2015

  • Patient recruitment for lung cancer and HIV studies completed
  • R&D expenses were on a par with reference period
  • Outlook for 2015 unchanged

09.11.2015

The biotechnology company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presented data on the immunotherapy MGN1703 at 2015 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor,...

30.10.2015

The biotechnology company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) has achieved the recruitment goal with the inclusion of currently 101 patients for the IMPULSE clinical study in lung cancer.

24.09.2015

The biotechnology company MOLOGEN AG will present a poster on the immunotherapy MGN1703 at the European Cancer Congress (ECC 2015) in Vienna (September 25 – 29, 2015).

22.09.2015

The biotechnology company MOLOGEN AG announced today that its partner, the Danish Aarhus University Hospital, completed enrollment of 16 HIV patients for the phase I TEACH study with the immunotherapy MGN1703. Results are expected in the second...

16.09.2015

The biotechnology company MOLOGEN AG is presenting two posters on the immunotherapies MGN1703 and MGN1601 at the Inaugural International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR) in New York (September 16 – 19, 2015).

   

Displaying results 1 bis 7 von 18

Page 1

Page 2

Page 3

next

   

Share Subscription Facility with US investor GCF

Further Information

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.